SISVEL
9.5.2024 11:41:30 CEST | Business Wire | Press release
A new agreement between Nordic Semiconductor and patent pool administrator Sisvel for the licensing of standard essential patents (SEPs) reading on LTE-M and NB-IoT cellular technology has been announced. The agreement creates a framework for easy and transparent access to the LTE-M and NB-IoT radio technology standards for a diverse range of IoT applications.
Specifically, the initiative provides a simple, efficient way for IoT device makers to obtain end-product licences from more than 30 patent owners holding LTE-M and NB-IoT SEPs, through Nordic as the cellular module supplier.
The agreement addresses the challenges posed by the diversity within the cellular IoT market, in which a multitude of companies - from startups to established corporations - are innovating. The wide range of significant initiatives being rolled out in areas such as smart-health, smart-energy, smart-cities and asset-tracking are currently at risk of stalling because of the lack of predictability and transparency in the access to and the cost of SEP licensing.
By offering standardised licences the agreement will reduce business uncertainty and the possibility of litigation. This will allow companies to focus on what they do best - developing new, innovative products and services for the IoT market.
"Nordic Semiconductor has always been at the forefront of wireless technology and we understand the importance of accessible and standardised licensing for the advancement of the IoT industry," comments Øyvind Birkenes, Nordic’s EVP Long Range. "We believe that this solution is a significant step towards a more efficient future for cellular IoT development."
"We are thrilled to have a unique licensing programme for cellular IoT backed by more than 30 patent owners and we believe this new agreement with Nordic addresses a critical need in the IoT ecosystem," says Sisvel CEO Mattia Fogliacco. "Our goal is to create a balanced and transparent licensing environment that supports innovation and growth for all stakeholders."
“We have worked hard with Sisvel and the SEP owners in its pool over the last year to broker this agreement because the IoT market urgently needs transparency and predictability,” says Kristian Sæther, Nordic’s Product Director – Cellular IoT. “Existing SEP licensing in the IoT space is up-in-the-air, putting countless SMEs across the globe developing wireless products in limbo. This new agreement offers efficiency and predictability to our customers. We look forward to seeing our peers and competitors recognise the importance of this work, and joining the pool solution, so that the entire cellular IoT market can operate with more predictability, and on a level playing field.”
About Sisvel
Sisvel is driven by a belief in the importance of collaboration, ingenuity and efficiency to bridge the needs of patent owners and those who wish to access their technologies. In a complex and constantly evolving marketplace, our guiding principle is to create a level playing field with the development and implementation of flexible, accessible, commercialisation solutions.
About Nordic Semiconductor
Nordic Semiconductor is a complete end-to-end wireless connectivity solutions provider, with a world-leading position in Bluetooth Low Energy, and an emerging leader in Cellular IoT, NR+, and Wi-Fi wireless technologies, Matter, Thread, Zigbee, and power management. The company’s low power wireless solutions enable millions of IoT devices to connect. Using Nordic’s innovation, its customers and partners across the globe are changing societies and lives for the better by powering smarter, safer, and more sustainable solutions. Nordic’s world-class hardware, software, and development tools are amongst the most advanced in the world, and the company deliver a complete developer experience by offering ultra-low power wireless solutions that are easy to implement, with the best possible support.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240509154129/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom